Susceptibility of HIV-2 to approved and experimental antiretroviral drugs: implications for treatment

被引：0
|
作者：
Witvrouw, M
Pannecouque, C
De Clercq, E
Switzer, WM
Folks, TM
Heneine, W
机构：
[1] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium
[2] Ctr Dis Control & Prevent, Atlanta, GA USA
来源：
ANTIVIRAL THERAPY | 2002年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
143
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 50 条
  • [1] Antiretroviral treatment of HIV-2 infection
    de Mendoza, Carmen
    Requena, Silvia
    Caballero, Estrella
    Cabezas, Teresa
    Penaranda, Maria
    Jose Amengual, Maria
    Saez, Ana
    Belen Lozano, Ana
    Ramos, Jose M.
    Soriano, Vincent
    FUTURE VIROLOGY, 2017, 12 (08) : 461 - 472
  • [2] HIV-2 in the UK - management and antiretroviral treatment outcomes
    Sellers, P.
    Reeves, I.
    Dhairyawan, R.
    Limb, S.
    Anderson, J.
    Deayton, J.
    HIV MEDICINE, 2018, 19 : S16 - S16
  • [3] Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds
    Moranguinho, Ines
    Taveira, Nuno
    Bartolo, Ines
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
  • [4] HIV-2 infection in Senegal: virological failures and resistance to antiretroviral drugs (ARVs)
    Ba, Selly
    Dia-Badiane, Ndeye Mery
    Hawes, Stephen Edward
    Deguenonvo, Louise Fortes
    Sall, Fatima
    Ndour, Cheikh Tidiane
    Faye, Khadim
    Traore, Fatou
    Toure, Macoumba
    Sy, Marie Pierre
    Raugi, Dana Noelle
    Kiviat, Nancy Berenice
    Smith, Robert Alexander
    Seydi, Moussa
    Sow, Papa Salif
    Gottlieb, Geoffrey Scott
    PAN AFRICAN MEDICAL JOURNAL, 2019, 33
  • [5] Emergence of Multiclass Drug-Resistance in HIV-2 in Antiretroviral-Treated Individuals in Senegal: Implications for HIV-2 Treatment in Resouce-Limited West Africa
    Gottlieb, Geoffrey S.
    Badiane, Ndeye Mery Dia
    Hawes, Stephen E.
    Fortes, Louise
    Toure, Macoumba
    Ndour, Cheikh T.
    Starling, Alison K.
    Traore, Fatou
    Sall, Fatima
    Wong, Kim G.
    Cherne, Stephen L.
    Anderson, Donovan J.
    Dye, Stefanie A.
    Smith, Robert A.
    Mullins, James I.
    Kiviat, Nancy B.
    Sow, Papa Salif
    CLINICAL INFECTIOUS DISEASES, 2009, 48 (04) : 476 - 483
  • [6] Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis
    Witvrouw, M
    Pannecouque, C
    Switzer, WM
    Folks, TM
    De Clercq, E
    Heneine, W
    ANTIVIRAL THERAPY, 2004, 9 (01) : 57 - 65
  • [7] Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis
    Witvrouw, M
    Pannecouque, C
    Switzer, WM
    Folks, TM
    De Clercq, E
    Heneine, W
    ANTIVIRAL RESEARCH, 2004, 62 (02) : A36 - A36
  • [8] Antiretroviral therapy for HIV-2 infected patients
    Smith, NA
    Shaw, T
    Berry, N
    Vella, C
    Okorafor, L
    Taylor, D
    Ainsworth, J
    Choudhury, A
    Daniels, RS
    El-Gadi, S
    Fakoya, A
    Moyle, G
    Oxford, J
    Tedder, R
    O'Shea, S
    de Ruiter, A
    Breuer, J
    JOURNAL OF INFECTION, 2001, 42 (02) : 126 - 133
  • [9] HIV-2 Susceptibility to Entry Inhibitors
    Borrego, Pedro
    Taveira, Nuno
    AIDS REVIEWS, 2013, 15 (01) : 49 - 61
  • [10] Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy
    Rodés, B
    Sheldon, J
    Toro, C
    Jiménez, V
    Alvarez, MA
    Soriano, V
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (04) : 709 - 713
12345